Evolutionary Tree Capital Management, LLC Arrowhead Pharmaceuticals, Inc. Transaction History

Evolutionary Tree Capital Management, LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$27.21 - $39.48 $184,783 - $268,108	-6,791 Reduced 13.14%	44,896 $1.28 Million
Q4 2023 Feb 13, 2024	BUY	$21.2 - $31.03 $8,925 - $13,063	421 Added 0.82%	51,687 $1.58 Million
Q3 2023 Nov 13, 2023	SELL	$26.2 - $36.08 $19,492 - $26,843	-744 Reduced 1.43%	51,266 $1.38 Million
Q2 2023 Aug 10, 2023	BUY	$25.16 - $41.38 $3,321 - $5,462	132 Added 0.25%	52,010 $1.85 Million
Q1 2023 May 09, 2023	SELL	$23.68 - $38.51 $952,338 - $1.55 Million	-40,217 Reduced 43.67%	51,878 $1.32 Million
Q4 2022 Feb 14, 2023	BUY	$28.0 - $40.56 $421,288 - $610,265	15,046 Added 19.53%	92,095 $3.74 Million
Q3 2022 Nov 10, 2022	BUY	$29.63 - $48.31 $349,930 - $570,541	11,810 Added 18.1%	77,049 $2.55 Million
Q2 2022 Aug 11, 2022	SELL	$27.79 - $50.61 $653,342 - $1.19 Million	-23,510 Reduced 26.49%	65,239 $2.3 Million
Q1 2022 May 13, 2022	SELL	$39.62 - $69.97 $1.06 Million - $1.88 Million	-26,831 Reduced 23.21%	88,749 $4.08 Million
Q4 2021 Feb 11, 2022	BUY	$58.09 - $82.51 $586,070 - $832,443	10,089 Added 9.56%	115,580 $7.66 Million
Q3 2021 Nov 12, 2021	BUY	$58.38 - $84.96 $1.62 Million - $2.35 Million	27,676 Added 35.57%	105,491 $6.59 Million
Q2 2021 Aug 12, 2021	BUY	$62.15 - $90.32 $302,484 - $439,587	4,867 Added 6.67%	77,815 $6.45 Million
Q1 2021 May 14, 2021	BUY	$61.35 - $90.47 $1.51 Million - $2.23 Million	24,683 Added 51.14%	72,948 $4.84 Million
Q4 2020 Feb 10, 2021	BUY	$43.82 - $85.37 $2.11 Million - $4.12 Million	48,265 New	48,265 $3.7 Million

295

92.3M

1.33M

549K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.03B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Evolutionary Tree Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Evolutionary Tree Capital Management, LLC with notifications on news.